Proteins.1 Emerges from VTT with Single-Molecule Protein Amplification Tech
Event summary
- Proteins.1 launched April 16, 2026 with €4.7M pre-seed funding to commercialize single-molecule protein amplification technology.
- The startup's physics-based platform aims for up to 1,000x greater sensitivity than current gold-standard diagnostics.
- Initial focus on research-use-only applications in oncology, neurology, and immunology before progressing to clinical diagnostics.
- Technology replaces enzymatic signal amplification with magnetic cycling mechanism for repeated single-molecule reading.
The big picture
Proteins.1 represents a potential paradigm shift in diagnostics, offering PCR-like amplification for proteins that could enable earlier disease detection. The technology addresses a critical gap in current diagnostic capabilities, where protein biomarkers often provide the earliest signals of disease onset but lack equivalent amplification methods to genetic material. With €4.7M in pre-seed funding and strong European backing in photonics and precision engineering, the startup positions itself at the forefront of next-generation diagnostic innovation.
What we're watching
- Technological Validation
- Whether the physics-based amplification can maintain signal clarity without increasing background noise in real-world applications.
- Regulatory Pathway
- The pace at which Proteins.1 progresses from research-use-only to regulated clinical diagnostics.
- Market Adoption
- How the €100B+ global diagnostics market responds to this new category of ultra-sensitive protein detection.
Our editorial coverage:
Related topics